NDAOPHTHALMICSOLUTION
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tetracaine hydrochloride is a topical ophthalmic anesthetic solution approved in 2019 for use in eye procedures and examinations. It is a local anesthetic that works by blocking nerve conduction in the cornea and conjunctiva. The drug is administered as an ocular drop to numb the eye surface prior to diagnostic or surgical interventions.
Peak
Product is in peak commercial stage with moderate competitive pressure (30%), indicating stable revenue but potential need for differentiation strategies to maintain market position.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on tetracaine hydrochloride offers career exposure to specialized ophthalmic markets and procedure-based selling in a stable, peak-stage product. Roles focus on defending market share and optimizing clinical adoption among ophthalmology practices rather than launch execution.
Brand ManagerField Sales Representative
Worked on TETRACAINE HYDROCHLORIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.